Botucatu School of Medicine, UNESP, Botucatu, Brazil.
Clinical Hospital of Botucatu Medical School, Botucatu, Brazil.
Int Urol Nephrol. 2020 Oct;52(10):1915-1922. doi: 10.1007/s11255-020-02512-z. Epub 2020 Jun 3.
While considerable information is available on acute kidney injury (AKI) in North America and Europe, large comprehensive epidemiologic studies on AKI from Latin America and Asia are still lacking. The present study aimed to evaluate the epidemiology and outcomes of AKI in patients evaluated by nephrologists in a Brazilian teaching hospital.
We performed a large retrospective observational study that looked into the epidemiology of AKI and its effect on patient outcomes across time periods. For comparison purposes, patients were divided into two groups according to the year of follow up: 2011-2014 and 2015-2018.
We enrolled 7976 AKI patients and, after excluding patients with chronic kidney disease stages 4 and 5, kidney transplant recipients and those with incomplete data, 5428 AKI patients were included (68%). The maximum AKI stage was 3 (50.6%), and there was a mortality rate of 34.3% (1865 patients). Dialysis treatment was indicated in 928 patients (17.1%). Patient survival improved along the study periods, and patients treated in 2015-2018 had a relative risk death reduction of 0.89 (95% CI 0.81-0.98, p = 0.02). The independent risk factors for mortality were sepsis, > 65 years of age, admission to the intensive care unit, AKI-KDIGO 3, recurrent AKI, no metabolic and fluid demand to capacity imbalance (as a dialysis indication), and the period of treatment.
We observed an improvement in AKI patient survival over the years, even after correction for several confounders and using a competing risk approach. Identification of risk factors for mortality can help in decision-making for timely intervention, leading to better clinical outcomes.
尽管北美的急性肾损伤 (AKI) 和欧洲有大量相关信息,但拉丁美洲和亚洲的 AKI 大型综合流行病学研究仍相对缺乏。本研究旨在评估巴西教学医院肾病医生评估的 AKI 患者的流行病学和结局。
我们进行了一项大型回顾性观察性研究,调查 AKI 的流行病学及其对不同时间段患者结局的影响。为了进行比较,根据随访年份将患者分为两组:2011-2014 年和 2015-2018 年。
我们共纳入了 7976 例 AKI 患者,在排除慢性肾脏病 4 期和 5 期、肾移植受者和资料不完整的患者后,共纳入 5428 例 AKI 患者(68%)。AKI 分期最高为 3 期(50.6%),死亡率为 34.3%(1865 例)。928 例(17.1%)患者需要透析治疗。随着研究时间的推移,患者的存活率有所提高,2015-2018 年接受治疗的患者死亡相对风险降低了 0.89(95%CI 0.81-0.98,p=0.02)。死亡的独立危险因素为脓毒症、>65 岁、入住重症监护病房、AKI-KDIGO 3 期、复发性 AKI、无代谢和液体需求与容量失衡(作为透析指征)以及治疗期间。
即使在校正了几个混杂因素并使用竞争风险方法后,我们观察到 AKI 患者的生存率在这几年中仍有所提高。识别死亡的危险因素有助于做出及时干预的决策,从而改善临床结局。